Rhona Scott

901 total citations
10 papers, 498 citations indexed

About

Rhona Scott is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rhona Scott has authored 10 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Endocrinology, Diabetes and Metabolism, 2 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rhona Scott's work include Diabetes Treatment and Management (4 papers), Diabetes Management and Research (4 papers) and Global Public Health Policies and Epidemiology (2 papers). Rhona Scott is often cited by papers focused on Diabetes Treatment and Management (4 papers), Diabetes Management and Research (4 papers) and Global Public Health Policies and Epidemiology (2 papers). Rhona Scott collaborates with scholars based in United Kingdom, United States and Spain. Rhona Scott's co-authors include Murray Stewart, Susan Johnson, Michael A. Nauck, Anthony Barnett, Richard E. Pratley, Julio Rosenstock, Fernando Ovalle, June Ye, Mark N. Feinglos and Austyn Snowden and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Diabetes Care.

In The Last Decade

Rhona Scott

7 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rhona Scott United Kingdom 6 377 203 140 103 66 10 498
Isaias Noel Gendrano United States 11 237 0.6× 63 0.3× 70 0.5× 78 0.8× 64 1.0× 20 450
Elisa Nada Italy 9 342 0.9× 87 0.4× 106 0.8× 52 0.5× 51 0.8× 23 436
Kotoba Okuyama Japan 11 352 0.9× 160 0.8× 151 1.1× 70 0.7× 136 2.1× 23 537
Paris Roach United States 16 526 1.4× 184 0.9× 254 1.8× 42 0.4× 24 0.4× 30 672
S. M. A. Bennett United Kingdom 5 291 0.8× 118 0.6× 52 0.4× 62 0.6× 62 0.9× 9 563
Juan Carlos Obaya Spain 9 189 0.5× 63 0.3× 99 0.7× 73 0.7× 24 0.4× 45 480
Giovanni La Croce Italy 14 93 0.2× 66 0.3× 189 1.4× 49 0.5× 39 0.6× 50 515
Barbara Tartaglino Italy 9 216 0.6× 63 0.3× 87 0.6× 17 0.2× 45 0.7× 20 321
Steven B. Leichter United States 15 317 0.8× 70 0.3× 94 0.7× 19 0.2× 27 0.4× 48 558
Sara Stafford Canada 8 362 1.0× 231 1.1× 142 1.0× 13 0.1× 226 3.4× 12 639

Countries citing papers authored by Rhona Scott

Since Specialization
Citations

This map shows the geographic impact of Rhona Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhona Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhona Scott more than expected).

Fields of papers citing papers by Rhona Scott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhona Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhona Scott. The network helps show where Rhona Scott may publish in the future.

Co-authorship network of co-authors of Rhona Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Rhona Scott. A scholar is included among the top collaborators of Rhona Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhona Scott. Rhona Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Diacon, Andreas H., Clifton E. Barry, Ray Y. Chen, et al.. (2024). A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature Medicine. 30(3). 896–904. 20 indexed citations
3.
Powell, Marcy, Jeanne M. Pimenta, Kathleen J. Beach, et al.. (2021). Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study. American Journal of Perinatology. 40(10). 1135–1148.
4.
Addo, Juliet, et al.. (2020). Supporting the next generation of non-communicable disease research leaders in Africa – experience of the GSK Africa NCD Open Lab. SHILAP Revista de lepidopterología. 4. 1 indexed citations
5.
Pratley, Richard E., Michael A. Nauck, Anthony Barnett, et al.. (2014). Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. The Lancet Diabetes & Endocrinology. 2(4). 289–297. 264 indexed citations
6.
Young, Malcolm A., Jeffrey A. Wald, Jessica Matthews, et al.. (2014). Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist. Postgraduate Medicine. 126(7). 84–97. 30 indexed citations
7.
Leiter, Lawrence A., Molly C. Carr, Murray Stewart, et al.. (2014). Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study. Diabetes Care. 37(10). 2723–2730. 79 indexed citations
9.
Snowden, Austyn, et al.. (2012). Helping the clinician help me: towards listening in cancer care. British Journal of Nursing. 21(Sup10). S18–S26. 5 indexed citations
10.
Snowden, Austyn, et al.. (2011). The clinical utility of the Distress Thermometer: a review. British Journal of Nursing. 20(4). 220–227. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026